Cardiff Oncology's Onvansertib Shows Promise, But Phase 3 Needs Cash

SAN DIEGO, CA – November 12, 2026 – In the high-stakes arena of oncology drug development, the line between a scientific breakthrough and a commercial triumph is often drawn by the balance sheet. Cardiff Oncology’s third-quarter 2026 financial results and business update, released today, perfectly encapsulate this modern biotech paradox. The San Diego-based company has delivered clinical data that could fundamentally disrupt the standard of care for one of the most notoriously difficult-to-treat cancers. Yet, as it stands on the precipice of a pivotal Phase 3 trial, the clinical-stage biotechnology company faces a stark reality: it must secure a significant capital injection to cross the finish line.

For leaders navigating the intersection of healthcare innovation and corporate strategy, Cardiff’s current position offers a masterclass in the complexities of bringing a novel therapeutic to market. The company is targeting RAS-mutated metastatic colorectal cancer (mCRC), a disease profile that has historically frustrated oncologists and pharmaceutical giants alike. With its lead asset, onvansertib, Cardiff is not just showing incremental progress; it is demonstrating unprecedented durability in patient responses. However, translating that clinical durability into a commercial reality will require deft financial maneuvering in the coming months.

Cracking the Pan-RAS Barrier

To understand the significance of Cardiff’s clinical data, one must first understand the biological fortress they are attempting to breach. RAS mutations are present in a vast number of solid tumors and have long been considered undruggable. While recent years have seen the advent of KRAS G12C inhibitors—such as those developed by Amgen and Mirati Therapeutics—these allele-specific drugs only target a minuscule fraction (less than four percent) of colorectal cancers. They are also typically relegated to later lines of therapy.

Cardiff has taken a radically different, mutation-agnostic approach. Instead of trying to inhibit the mutated RAS protein directly, onvansertib targets PLK1, a serine/threonine kinase that operates downstream of RAS. Because PLK1 activity is upregulated in RAS-driven tumors, inhibiting it creates a targeted vulnerability. This mechanism allows onvansertib to potentially treat a much broader pan-RAS patient population, bypassing the limitations of allele-specific inhibitors.

The results from the ongoing randomized Phase 2 trial evaluating onvansertib in combination with standard-of-care FOLFIRI and bevacizumab in first-line RAS-mutated mCRC are striking. According to the company's latest update, the median progression-free survival (PFS) has not yet been reached in the 30 mg onvansertib combination arm. For context, the median PFS in the combined standard-of-care arms has been reached at approximately 11 months, a figure that aligns perfectly with historical benchmarks.

Even more compelling is the durability of the response. As of late September 2026, all patients remaining in the 30 mg onvansertib plus FOLFIRI/bevacizumab arm have been on treatment for at least 21 months, with the longest duration exceeding 29 months. Furthermore, the 30 mg arm achieved a confirmed objective response rate of 72.2 percent, a massive 30-percentage-point improvement over the 42.1 percent observed in the standard-of-care alone cohort.

“We’re greatly encouraged by the performance of onvansertib in first-line RAS-mutated mCRC. As the data mature, the benefit of onvansertib in combination with FOLFIRI/bev is becoming more evident, with growing separation between the onvansertib and control arms,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology.

Clinical Triumph Meets Cash Reality

Despite the undeniable clinical momentum, Cardiff’s third-quarter financial disclosures reveal a ticking clock. As of September 30, 2026, the company reported holding approximately $33.8 million in cash, cash equivalents, and short-term investments. While net cash used in operating activities for the first nine months of the year was kept to $33.9 million—and the third-quarter net loss narrowed to $8.9 million from $11.3 million a year prior—the current treasury is insufficient to independently fund the next critical phase of development.

Cardiff expects to initiate its registrational Phase 3 trial in the first quarter of 2027. However, management explicitly noted that this timeline is subject to securing additional financing. Launching a global, multi-center Phase 3 oncology trial is an exceptionally capital-intensive endeavor, often requiring tens to hundreds of millions of dollars. The company's current cash runway is projected to last only into the third quarter of 2027.

This dynamic places Cardiff in a delicate strategic position. The company recently completed a $10 million registered direct offering in July 2026 to bolster working capital, but a much larger financial vehicle will be required soon. Industry observers note that the company will likely need to explore non-dilutive partnership deals, royalty financing, or a larger equity raise to fund the Phase 3 study. The challenge for Cardiff’s executive team will be negotiating from a position of strength based on their Phase 2 data, rather than a position of weakness based on their cash runway.

Legal Clarity and Strategic Pipeline Expansion

Recognizing the need to present a pristine corporate profile to potential partners and institutional investors, Cardiff has spent the latter half of 2026 aggressively derisking its operations. A major overhang was removed in September when the company resolved all outstanding disputes with its licensor, Nerviano Medical Sciences S.r.l.

The dispute regarding global rights to onvansertib had previously inflated selling, general, and administrative expenses, which rose by $3.1 million over the first nine months of 2026 largely due to associated legal and professional fees. With the 2017 exclusive license agreement now amended and the legal friction eliminated, Cardiff has secured unencumbered control over its lead asset just as it prepares for pivotal trials.

Simultaneously, the company is expanding the regulatory footprint of onvansertib. In October and November of 2026, the U.S. Food and Drug Administration granted Orphan Drug Designation to onvansertib for the treatment of chronic myelomonocytic leukemia and small cell lung cancer, respectively. These designations not only validate the drug's mechanism of action across multiple hard-to-treat indications but also offer valuable incentives, including extended market exclusivity upon potential approval.

To guide this expanding clinical mandate, Cardiff appointed Dr. Leila Alland as interim Chief Medical Officer in October. Bringing a wealth of experience from leadership roles at AstraZeneca, Bristol Myers Squibb, and Novartis, Dr. Alland’s appointment signals a maturation of Cardiff’s clinical operations as it transitions from exploratory studies to registrational execution.

The Road Ahead for PLK1 Inhibition

As 2026 draws to a close, Cardiff Oncology stands at a critical inflection point. The company has successfully completed an End-of-Phase 2 meeting with the FDA, aligning on a Phase 3 trial design that will compare the 30 mg onvansertib regimen against standard of care. The trial is strategically engineered to support a potential accelerated approval based on objective response rate, with full approval contingent on progression-free survival.

“Building on the strength of these data, we are actively preparing for our upcoming registrational trial,” Dr. Mohindru noted in the quarterly update. “There are currently no treatment options specifically approved for patients with pan-RAS-mutated mCRC in the first-line setting and we believe onvansertib has the potential to become an important new treatment for these patients.”

For industry analysts and prospective investors, the data presents a compelling narrative of a dose-dependent treatment benefit that achieves statistical significance even within the relatively small patient cohorts of a Phase 2 study. The biological rationale of PLK1 inhibition is proving out in the clinic, offering a beacon of hope for patients who have long been underserved by precision medicine.

The ultimate test for Cardiff Oncology, however, will not be conducted in a laboratory or a clinical setting, but in the boardrooms of potential financiers and strategic partners. The science has spoken; now, the business must deliver.